Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Single-dose, Parallel-group Study Comparing Pharmacokinetic Characteristics, Safety , Tolerability and Immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Avastin (Bevacizumab Injection) in Healthy Chinese Male Subjects
Conditions
Interventions
LY01008
Avastin
Locations
1
China
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Start Date
August 4, 2020
Primary Completion Date
January 13, 2021
Completion Date
January 13, 2021
Last Updated
November 5, 2021
NCT07446322
NCT07536113
NCT07416552
NCT07228832
NCT06625775
NCT04657068
Lead Sponsor
Shandong Boan Biotechnology Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions